Table 1 Data summary for the six studies selected for CQ/HCQ-induced myopathy.
Authors | Year | Country | Type of study/Level of evidence* | Total #Patients (genders F, M) | Patients treated with HCQ/CQ | Patient age in years mean/SD | Dosages (mg for daily dose; gr for cumulative dose) | Duration (years mean or mean range) | Primary diseases |
|---|---|---|---|---|---|---|---|---|---|
Wang et al.32 | 1999 | Canada | Prospective study/Level III-2 | 224 (136F, 88NR) | 156 HCQ or CQ | 34 ± 14 | 200 to 400 mg/day HCQ | 4.2 ± 5.6 | SLE (number of patients) |
Casado et al.9 | 2005 | Spain | Prospective study/Level III-2 | 119 (84 F, 35 M) | 111 CQ/8 HCQ | 57.5 ± 13.9 | 3.5 mg/kg/day QC, 6.5 mg/kg/day HQC | 3 (40.4 months) | RA [69], PR [14], SS [11], SLE [9], , CT [7], psoriatic arthritis [4], and other rheumatic conditions [5] |
Kalajian et al.33 | 2009 | USA | Prospective study/Level III-2 | 21 (20 F, 1 M) | 8 CQ/13 HCQ | 51. 7 ± 11.37 | minimum of 200 mg of HQC or 250 mg of QC/daily | 0.25–9.0 | LE |
Tselios et al.23* | 2016 | Canada | Retrospective Case Control study/Level III-3 | 1778 87.1% F (cases), 87.8% F (controls) | 186CQ/806 HCQ# | 41.85 ± 14.45a 43.86 ± 15.95b | 155.11gr of CQ (a) 341.55gr of HCQ (a) 89gr of CQ (b) 355gr of HCQ (b) | 3.84–4.33 | SLE |
Khoo et al.5 | 2017 | Australia | Retrospective Case Control study/Level III-3 | 34 (NR) | 18 | NR | 200 mg–800 mg | 0.35–11.58 | Inflammatory Myositis |
